Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
120
NCT07188896
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Phase: Phase 2
Role: Lead Sponsor
Start: Nov 30, 2025
Completion: Nov 30, 2030